Open‐Label, Non‐Mandatory Transitioning From Originator Etanercept to Biosimilar SB4

Objective To evaluate the effects of non‐mandatory transitioning from the originator biologic drug etanercept ( ETN ) to its biosimilar, SB 4, on drug survival and effectiveness in a controlled cohort study of patients with an inflammatory rheumatic disease. Methods In 2016, 642 patients were asked to transition their treatment from originator ETN to biosimilar SB 4 by a structured communication strategy with opt‐out option. Patients who...